Manning & Napier Group's BSX Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 100 shares of Boston Scientific Corporation (BSX) worth $4,348, representing 0.00% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Manning & Napier Group has maintained a strategic position in BSX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 102,028 shares. Largest reduction occurred in Q2 2024, reducing 258,118 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Boston Scientific Corporation (BSX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Boston Scientific Corporation (BSX) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +100 | New Buy | 100 | $43.48 |
| Q2 2024 | -258,118 | Sold Out | 0 | $0.00 |
| Q1 2024 | -41,457 | Reduce 13.84% | 258,118 | $68.48 |
| Q4 2023 | -1,277 | Reduce 0.42% | 299,575 | $57.81 |
| Q3 2023 | -162,021 | Reduce 35.00% | 300,852 | $52.80 |
| Q2 2023 | -5,326 | Reduce 1.14% | 462,873 | $54.09 |
| Q1 2023 | +102,028 | Add 27.86% | 468,199 | $50.03 |
| Q4 2022 | -39,647 | Reduce 9.77% | 366,171 | $46.27 |
| Q3 2022 | -579 | Reduce 0.14% | 405,818 | $38.73 |
| Q2 2022 | -25,186 | Reduce 5.84% | 406,397 | $37.27 |
| Q1 2022 | -12,000 | Reduce 2.71% | 431,583 | $44.29 |
| Q4 2021 | -880 | Reduce 0.20% | 443,583 | $42.48 |
| Q3 2021 | -2,205 | Reduce 0.49% | 444,463 | $43.39 |
| Q2 2021 | -13,931 | Reduce 3.02% | 446,668 | $42.76 |
| Q1 2021 | +31,853 | Add 7.43% | 460,599 | $38.65 |
| Q4 2020 | +44,862 | Add 11.69% | 428,746 | $35.95 |
| Q3 2020 | -5,641 | Reduce 1.45% | 383,884 | $38.21 |
| Q2 2020 | +15,369 | Add 4.11% | 389,525 | $35.11 |
| Q1 2020 | -121,225 | Reduce 24.47% | 374,156 | $32.63 |
| Q4 2019 | -40,095 | Reduce 7.49% | 495,381 | $45.22 |
| Q3 2019 | -70,410 | Reduce 11.62% | 535,476 | $40.69 |
| Q2 2019 | +605,886 | New Buy | 605,886 | $42.98 |
Manning & Napier Group's Boston Scientific Corporation Investment FAQs
Manning & Napier Group first purchased Boston Scientific Corporation (BSX) in Q2 2019, acquiring 605,886 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Boston Scientific Corporation (BSX) for 22 quarters since Q2 2019.
Manning & Napier Group's largest addition to Boston Scientific Corporation (BSX) was in Q2 2019, adding 605,886 shares worth $26.04 M.
According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 100 shares of Boston Scientific Corporation (BSX), valued at approximately $4,348.
As of the Q2 2026 filing, Boston Scientific Corporation (BSX) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Boston Scientific Corporation (BSX) was 605,886 shares, as reported at the end of Q2 2019.